Basilea Pharmaceutica’s work developing new antifungals has received a significant boost from the U.S. Department of Health and Human Services, which has signed off on up to $268 million of funding to the Swiss company over more than a decade.

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 million for its “plug-and-play” tech developed in the lab of—and with cells from—George Church, Ph.D.

The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an intention to go public.

With COVID-19 still spreading and mpox emerging as a public health emergency of international concern, the National Institutes of Health (NIH) is upping preparations for future pandemics.

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting cells outside the liver.

Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, Japan’s Nippon Shinyaku has signed off on $35 million in cash and a stock purchase to secure the same deal in Europe.

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense continuous glucose monitoring system that only needs to be swapped out once per year.

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, boosting plans to take a second shot at FDA approval. But two more people died after developing interstitial lung disease (ILD), and the overall survival (OS) data are immature.

Ascendis Pharma has emerged as a potential threat to BioMarin’s Voxzogo, reporting phase 3 growth disorder data that exceeded analyst expectations and position the biotech to file for approval next year.

For Ichnos Glenmark Innovation, good things come in threes. The alliance between Ichnos Sciences and Glenmark Pharmaceuticals has developed a trispecific, T-cell activating antibody that shrank multiple myeloma tumors in mice and killed cancer cells in human tissue more effectively than Johnson & Johnson’s Tecvayli.